Drug development

#Biology #Drug development #Therapeutics

Closing drug development gaps with new clinical prediction AI 

Quris, an artificial intelligence (AI) company in the pharmaceutical industry, has launched a clinical prediction AI platform to predict which drug candidates will safely work in humans. This will improve efficacy and cut drug development costs.   What do they do?  Quris uses AI-powered miniaturised “patients-on-a-chip” to avoid… Read More

#News #Videos

#Drug development #Drug innovation #Microbiology

BaseClear appoints new CSO to lead its science and innovation arm 

BaseClear has appointed Alex Van Belkum as Chief Scientific Officer. He is a molecular microbiologist with extensive experience in molecular- and culture-based diagnostics, antimicrobial resistance testing and clinical microbiology. He will lead BaseClear’s science and innovation arm together with Innovation Manager Walter Pirovano and a team of PhD-level Product Managers.   Official comment… Read More

#News

#3D modelling #DNA #Drug development #Library screening #Screening

NovAliX enters partnership to design and screen new DNA-encoded libraries 

NovAliX, a CRO specialising in drug research and development, has partnered with Sanofi for the development of new DNA-Encoded Libraries (DELs), allowing the partners to design both general and focused chemical libraries, and carry out screening activities to identify new and useful chemical structures.  Why is this useful? … Read More

#News

#Autoimmune disease #Biology #Drug development #Drug discovery #Research study #Therapeutics

Human-on-a-Chip approach validated to model rare autoimmune disease

A new peer-reviewed article demonstrated that Hesperos’ Human-on-a-Chip (HoaC) cell-based neuromuscular junction (NMJ) platform system can mimic the disease phenotypes of myasthenia gravis (MG). The manuscript, titled “A Functional Human-on-a-Chip Autoimmune Disease Model of Myasthenia Gravis for Development of Therapeutics,” was published in Frontiers in Cell and Developmental Biology. Read More

#News

#Biopharmaceuticals #Drug development #Drug discovery #Immunology / Virology & Vaccines #In vivo

Agreement to develop vaccines against cancer and infectious diseases 

Nykode Therapeutics (formerly Vaccibody) has entered into a license and collaboration agreement with Regeneron for the discovery, development and commercialisation of potential new vaccines for cancer and infectious diseases.  What is the structure of the agreement?  The agreement includes five programmes, three within cancer and two within infectious diseases. Read More

#News

Human liver
#Cancer research #Drug development #Immunology / Virology & Vaccines #Liver disease #Research

Does Hepatitis B virus support the survival and growth of liver cancer? 

Researchers at the Francis Crick Institute and Universidade de Santiago de Compostela have identified how the hepatitis B virus (HBV) can support the survival and growth of liver cancer, with this process starting early in tumour development, in some instances up to 20 years before cancer diagnosis.  Context  Around… Read More

#Cancer Research #News

#CAR-T #DNA #Drug development #Drug discovery #Podcast #Synthetic biology

Podcast: Building on current drug discovery methods

This is the latest episode of the free DDW podcast, “Building on current drug discovery methods”. It covers two narrated article written for Volume 22, Issue 2 – Spring 2021 of DDW and read aloud by Megan Thomas. The articles are called “The new synthesis: How synthetic DNA technology is… Read More

#News #Trending News

#Collaboration #Drug development #Funding

Benchling announces $100 million funding and continued expansion 

Benchling is continuing its European expansion, following a strong year of growth. This expansion comes as Benchling reveals it has raised $100 million in Series F funding at a $6.1 billion valuation.   Context  The company achieved triple-digit year-over-year revenue growth in the market in its most recent fiscal… Read More

#News

#Drug development #Drug discovery #GlobalData #siRNA #Therapeutics

Chinese pharma companies eye strategic alliances for therapeutics

The overall potential of siRNA-based therapeutics has attracted Chinese pharma companies to tap opportunities and bring promising innovative therapies across the globe, according to reporting by GlobalData. Against this backdrop, the Chinese pharma companies have increased their focus towards the siRNA pipeline through strategic alliances.  China pharma… Read More

#News #Trending News

Human brain
#Drug development #Drug discovery #Healthcare #Neuroscience #Pharmaceuticals

NICE approves drug which treats EDS caused by narcolepsy 

Jazz Pharmaceuticals’ Sunosi (solriamfetol) has been issued a positive Final Appraisal Document (FAD) from the National Institute for Health and Care Excellence (NICE), recommending the drug for adults with excessive daytime sleepiness (EDS) caused by narcolepsy.1  When is solriamfetol needed?  Solriamfetol is recommended as an option for treating EDS… Read More

#News #Trending News

#Drug development #Software

IDBS acquisition extends lifecycle management capabilities 

Global life sciences software company IDBS has acquired biopharmaceutical manufacturing data management and analytics software developer Skyland Analytics, in a move that will create the first BioPharma Lifecycle Management (BPLM) offering that supports therapies from early development through commercial manufacturing.   Context  More than half of… Read More

#News

#AI / data analytics / healthtech / informatics #AstraZeneca #Drug development #Funding #Research #Technology

Next wave of innovation: AstraZeneca £1bn R&D centre 

AstraZeneca has unveiled The Discovery Centre (DISC) in Cambridge, UK – a research and development (R&D) facility designed to the world’s highest environmental standards and accommodating over 2,200 research scientists.  The new £1 billion facility will include advanced robotics, high-throughput screening and AI-driven technology. It will support AstraZeneca’s focus… Read More

#News

Handshake
#Autoimmune disease #Collaboration #Drug development #Drug targets #Funding #Partnership

Agreement to develop drug target for multiple autoimmune diseases 

Affibody partnered with ACELYRIN to develop and commercialise izokibep, a bispecific molecule targeting interleukin-17A (IL-17), for multiple autoimmune diseases.   Izokibep is an antibody mimetic, IL-17A inhibitor designed to overcome the limitations of monoclonal antibodies. With extraordinary potency and small molecular size, izokibep can reach high drug exposure levels through a single subcutaneous… Read More

#News

#Data #Drug development #Drug discovery #Genomics #Research study #Tuberculosis

Largest ever global TB study identifies genetic causes of drug resistance 

The Comprehensive Resistance Prediction for Tuberculosis International Consortium (CRyPTIC) research project has reportedly collected the largest ever global dataset of clinical M. tuberculosis samples from across the world consisting of 15,211 samples from 27 countries on five continents.  Using a new quantitative test for drug resistance and… Read More

#News #Trending News

#Cell therapy #Drug development #Drug discovery #Immunology

Bone marrow backup needed to tackle respiratory infections 

Scientists at the Francis Crick Institute have found how the immune system triggers an ‘emergency’ dendritic cell response during infection, with dendritic cells at the site of infection being reinforced by new cells which travel from the bone marrow.   Dendritic cells have an important role in the… Read More

#News #Trending News

#Clinical trials #Covid-19 #Drug development #Immunology / Virology & Vaccines

T-cell vaccines may offer “significant benefits” over current Covid-19 vaccines 

Emergex Vaccines has announced that it has received the necessary regulatory approvals to initiate a Phase I clinical trial to evaluate the safety and tolerability of its vaccine candidate for SARS-CoV-2.  The Phase I trial is a double-blind, randomised and comparator-controlled study of two groups of 13 volunteers at high… Read More

#Covid-19 #News